Hon tar över efter nedläggningarna – startar nytt in vivo-bolag i Stockholm

Två djurförsöksverksamheter i Stockholmsområdet lades ned och med det försvann prekliniska in vivo-tjänster från regionen. ”Bara för att två labb upphör att exi...

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Explore the possibilities of the new ZEISS METROTOM 800 320 kV

Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

Health politician Lina Nordquist: ”I find it hard to be idle”

She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decid...

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Många avbryter behandling med fetmaläkemedel – ny studie pekar ut orsakerna

I en ny studie kartläggs de vanligaste orsakerna till att patienter väljer att sluta med läkemedel mot obesitas i förtid. ”Hälsofördelar går förlorade när behan...

Digital Temperature Sensors from ZEISS

New Metrology Expert Tip video.

Alvotech flyttar in i svenskt life sciene-kluster

Isländska Alvotech, noterade på Stockholmsbörsen, flyttar in på Campus Solna. ”Alvotech strävar efter att avsevärt expandera sin forsknings- och utvecklingsverk...

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Ny svängning – Trump hotar med 100-procentiga tullar på läkemedel

USA kommer att införa 100-procentiga tullar på importerade läkemedel, såvida inte bolagen bygger fabriker på amerikansk mark, uppger president Donald Trump.

Johan Pehrson takes over the responsibility for research policy in Sweden

The Liberals' party leader Johan Pehrson takes over the assignment as Minister for Education. This was announced by Prime Minister Ulf Kristersson (M) on Tuesday last week.

The key to successful collaboration between industry and academia

Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?

Quotient Sciences Limited

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...